A new antiviral scaffold for human norovirus identified with computer-aided approaches on the viral polymerase by Salvatore, Ferla & Marcella, Bassetto
1Scientific RepoRtS |         (2019) 9:18413  | https://doi.org/10.1038/s41598-019-54903-7
www.nature.com/scientificreports
A new antiviral scaffold for human 
norovirus identified with computer-
aided approaches on the viral 
polymerase
Gilda Giancotti1, ilaria Rigo1, Gaia Pasqualetto1, Mark t. Young2, Johan Neyts3,  
Joana Rocha-Pereira3, Andrea Brancale1, Salvatore ferla  1* & Marcella Bassetto1,4
Human norovirus is the leading cause of acute gastroenteritis worldwide, affecting every year 685 
million people. In about one third of cases, this virus affects children under five years of age, causing 
each year up to 200,000 child deaths, mainly in the developing countries. Norovirus outbreaks are 
associated with very significant economic losses, with an estimated societal cost of 60 billion dollars 
per year. Despite the marked socio-economic consequences associated, no therapeutic options or 
vaccines are currently available to treat or prevent this infection. One promising target to identify new 
antiviral agents for norovirus is the viral polymerase, which has a pivotal role for the viral replication and 
lacks closely homologous structures in the host. Starting from the scaffold of a novel class of norovirus 
polymerase inhibitors recently discovered in our research group with a computer-aided method, 
different new chemical modifications were designed and carried out, with the aim to identify improved 
agents effective against norovirus replication in cell-based assays. While different new inhibitors of 
the viral polymerase were found, a further computer-aided ligand optimisation approach led to the 
identification of a new antiviral scaffold for norovirus, which inhibits human norovirus replication at 
low-micromolar concentrations.
Human norovirus (HuNoV) is the main cause of acute gastroenteritis worldwide, leading to approximately 
200,000 deaths every year, with an associated societal cost of 60 billion USD1. While infection with this 
virus is responsible for a self-limiting disease in healthy individuals, the condition often becomes severe or 
life-threatening in immune-compromised patients, children and the elderly2,3. Despite the serious health and 
economic consequences associated, no therapeutic options or vaccines are currently available4, attracting sig-
nificant research efforts into the identification of antiviral candidates, to be used to treat the infection and as a 
prophylactic measure in the case of outbreaks. Research into much needed anti-norovirus agents has been ham-
pered by several factors, including the inaccessibility of a cell-culture human norovirus propagation system until 
recently. Despite this, there are ways to study the antiviral effect of molecules by using murine norovirus (MNV), 
which represents a good surrogate, particularly regarding the viral enzymes involved in replication, and a HuNoV 
replicon cell line5,6. Currently, only a few antiviral agents are under evaluation in pre-clinical and clinical stages. In 
particular, two small-molecules are currently under clinical investigations: Nitazoxanide, an antiprotozoal agent 
which reduces the duration and alleviates the symptoms of norovirus infection with a still unknown mechanism 
of action7,8, and CMX521, a nucleoside analogue which shows efficacy against multiple viral genotypes9. Other 
therapeutic candidates in pre-clinical development include different agents targeting mainly the viral polymerase 
or protease, due to their essential roles in the viral replication and the absence of homologous host enzymes10–17.
As a member of the Caliciviridae family, norovirus is characterised by a single-stranded positive-sense RNA 
genome, which is replicated by the viral RNA-dependent RNA-polymerase (RdRp) function located in the viral 
non-structural protein NS718. As revealed by crystallographic data, norovirus polymerase structure highly 
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resembles the one of other positive-strand RNA viruses19, and its activity of RNA synthesis can be initiated de 
novo RNA or via a VPg-primed mechanism20. Due to its essential role in the viral replication, and to the repeat-
edly proven success of targeting viral polymerases in antiviral drug discovery21, norovirus RdRp has been pre-
viously chosen in our research group as a promising target for the identification of new anti-norovirus agents, 
focussing in particular on the identification of novel non-nucleoside inhibitors (NNIs) of this enzyme. A limited 
number of inhibitors of this type has been reported so far for norovirus RdRp, but the majority of these com-
pounds lack any activity against the viral replication in cellular systems, possibly due to poor cell permeability and 
drug-like properties22. As several crystal structures are available for human and murine norovirus polymerase, 
including ternary complexes with nucleotide analogues and with allosteric non-nucleoside inhibitors23–28, the 
study of these structures has been the starting point for a structure-based virtual screening study that led to the 
identification of our broad-spectrum Caliciviridae RdRp inhibitor 1 (Fig. 1)29. As is the case for other reported 
NNIs of norovirus RdRp, despite showing an enzyme inhibition in the low micromolar range, 1 was associ-
ated with a very mild effect against norovirus replication in cell-based systems, possibly due to its poor aqueous 
solubility. Moreover, this compound showed some cytotoxicity at relatively low concentrations, with a CC50 of 
~64 μM, possibly due, at least in part, to its low solubility and precipitation from the assay medium.
In the present study, the structure of 1 has been rationally modified in order to improve its drug-like prop-
erties and achieve an antiviral effect against norovirus replication in cell-systems. The novel structural modi-
fications carried out have allowed a better understanding of the functional groups required for enzymatic and 
antiviral activity, and the successful identification of a new anti-norovirus scaffold with antiviral EC50 values in 
the low micromolar range. This new scaffold represents a promising starting point for further optimisations and 
for the potential development of a viable treatment for norovirus infections.
Results and Discussion
Rational modifications on compound 1. 1 is characterised by a central 5-phenylfuran-2-ylmethyl-
ene-pyrazolidine-3,5-dione core (planar central linker in Fig. 1), substituted at position 1 of the pyrazolidine with 
a benzene ring (terminal hydrophobic ring 1), and at position 4 of the phenyl ring with a N-phenylsulfonamide 
(terminal hydrophobic ring 2). These structural features render 1 relatively hydrophobic (calculated logP (o/w) 
4.3) and poorly soluble, limiting its potential as a drug.
As described by Hashimoto et al.30, decreasing the logP of a molecule by introducing a hydrophilic group is a 
classical and general strategy for improving its aqueous solubility. Following this rationale, two main structural 
modifications have been planned for 1 to achieve this result: 1) the introduction of a carboxylic acid group at 
different positions of terminal hydrophobic ring 1 (compounds 2 and 3 in Fig. 1), which should also provide the 
potential for extra interactions with the RdRp active site; 2) the replacement of the terminal hydrophobic ring 2 
with different heteroaromatics (compounds 4–6 in Fig. 1). In particular, this second approach was designed as 
a consequence of our previously published work29, in which a thiazole derivative of 1 showed a better antiviral 
Figure 1. Structural features of previous hit 1 and strategies for the rational/computer-aided modification of its 
scaffold.
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activity in a cell-based assay (40% inhibition of murine norovirus (MNV)-induced plaque formation at 10 μM), 
without showing significant solubility issues, but was found to be relatively cytotoxic, with a low selectivity index. 
Both types of modifications increase the polarity of the original molecule, which could influence in a positive 
manner their antiviral activity against norovirus replication in cell-based systems. Moreover, as suggested above, 
the new modifications may improve the binding to the viral polymerase, better mimicking the polar phosphate 
groups present in the RNA natural substrate of this enzyme.
Another feature that is recognised to influence compound solubility in a negative fashion is molecular pla-
narity, which enhances crystal packing: poorly soluble compounds are often found to form very stable crystals, 
which are difficult to be broken by the solvent molecules31. Disruption of molecular planarity is usually reflected 
in improved solubility. As the structure of 1 is predominantly planar, an alternative strategy to reduce its solubility 
issues was to attempt to disrupt its planarity, by applying a scaffold replacement procedure using Schrödinger 
Core Hopping tool32. During this analysis, the two terminal hydrophobic rings were kept as fixed, while searching 
for alternative groups to replace the central planar core in 1. Among the different modifications generated by 
the program, a N-2-diphenylacetamide group was chosen as a more flexible linker to replace the phenylfuran
-2-ylmethylene-pyrazolidine-3,5-dione core, and the new compound 7 (Fig. 1) was designed. The new linker 
selection was driven by an overall molecular length preservation and synthetic accessibility. Despite penalising 
the new compound from a logP point of view (calculated logP (o/w) 5.3), the effect of the new central core on 
disrupting the planarity of 1 appears to be significant, as shown in Fig. 2.
Chemistry
Synthesis of compounds with modifications on the two terminal hydrophobic rings. A sev-
en-step synthetic pathway previously developed and optimised by our research group has been used for the 
preparation of a small family of seven new derivatives bearing modifications on the terminal hydrophobic ring 1 
or on ring 229.
As shown in Fig. 3, differently substituted phenylhydrazines (10–12, 37) were reacted with ethyl-3-chloro-
3-oxopropanoate 13 in THF and triethylamine (NEt3), giving the desired hydrazides 14–16, 38. Ester-susbtituted 
hydrazines 10–11 were prepared in a good yield by converting the differently substituted hydrazineylbenzoic 
acids 8–9 into the corresponding ethyl esters via Fisher esterification using hydrochloric acid (HCl) and etha-
nol (EtOH). An alternative approach was required for the preparation of the ortho ethyl ester 37. In fact, under 
Fisher reaction conditions, an intramolecular reaction between the carboxylic acid and the hydrazine group 
occurs, leading to the formation of 3-indanzolinone. The desired ethyl 2-hydrazineylbenzoate 37 was obtained 
by reacting the ethyl 2-aminobenzoate with sodium nitrite (NaNO2) in HCl, and then reducing the interme-
diate diazonium salt using tin chloride (SnCl2). Hydrazides 14–16 were converted into the corresponding 
1-arylpyrazolidine-3,5-diones 17–19 through an ester displacement reaction in the presence of sodium hydroxide 
(NaOH) and EtOH. Unfortunately, the synthesis of ortho substituted compound 39 could not be achieved, poten-
tially due to steric hindrance that impedes the cyclization reaction. Treatment of 4-bromobenzene-1-sulfonyl 
chloride (24) with the appropriate aniline (20–23) in pyridine produced sulfonamides 25–28, which were then 
converted into the aldehyde intermediates 30–33 by Suzuky coupling with (5-formylfuran-2-yl)boronic acid 
29. In particular, for compound 30, bearing the original phenyl group, our formerly reported conditions using 
potassium phosphate (K3PO4) as base, Pd(dppf) as catalyst, water/DMF as solvent and heating under microwave 
irradiation for 75 min at 130 °C25, gave the desired product, whereas no product could be obtained for derivatives 
31–33 in these reaction conditions. After exploring various alternative procedures, the best reaction conditions 
were found using sodium carbonate (Na2CO3) as base, Pd(OAc)2 and PPh3 as catalyst, water/DME as solvent, and 
heating the reaction mixture under microwave irradiation for 10 min at 85 °C, which gave the desired products 
in moderate yields (34–51%). The two portions were then linked together by reacting aldehydes 30–33 with the 
appropriate arylpyrazolidine-3,5-dione 17–19 according to a Knoevenagel condensation in acetic acid at 130 °C 
for 3 h, giving the desired products 5, 34–35. The derivatives showing a pyrimidine (4) and a 1H-benzoimidazole 
ring (6) appeared to degrade under these reaction conditions, therefore 4 was obtained using EtOH under reflux 
overnight, while 6 was prepared using methanol under reflux for 2 hours. In the last step, hydrolysis of the ethyl 
ester group was performed for 34 and 35. The para carboxylic acid derivative 2 was obtained by treating the 
starting ethyl ester with lithium hydroxide (LiOH) overnight at room temperature, while for the meta derivative 
3 sodium hydroxide (NaOH) and dioxane were used. In fact, using LiOH for the hydrolysis of 35 led to the for-
mation of a hydroxyl amine on the -NH group of the pyrazolidine-3,5-dione ring, with this hydroxylamine side 
product in a 50:50 ratio with the desired compound 3. The use of NaOH and dioxane limited significantly the side 
product formation.
Figure 2. Three-dimensional superimposition, calculated with the Alignment tool in MOE 201837, of the 
energetically minimised structures of 1, with carbon atoms in lilac, and 7, with carbon atoms in green-uniform. 
The new linker inserted in 7 significantly reduces the rigidity and planarity of the linker in 1.
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Synthesis of increased-flexibility analogue 7. Compound 7 was prepared in order to initially inves-
tigate the influence of the new central N,2-diphenylacetamide linker in the RdRp inhibitory activity, in order to 
preliminarily test the Core Hopping approach. The synthetic pathway reported in Fig. 4 was followed.
Sulfonamide 42 was prepared in almost quantitative yield by reacting aniline 40 and commercially available 
N-acetylsulfanilyl chloride 41 in pyridine at 0 °C. The ester group in 42 was then hydrolysed using NaOH in 
methanol to afford the free carboxylic acid 43. A Suzuki coupling reaction, using sodium carbonate (Na2CO3) as 
base and tetrakis (Pd[Ph]3]4) as catalyst, between phenylboronic acid 45 and methyl 2-(3-bromophenyl)acetate 
44, in a solvent mix of toluene/water/ethanol, gave compound 46 in good yield (75%). Hydrolysis of 46 with 
LiOH in water/methanol gave the free acid 47, which was then reacted with 43 in dimethylformamide (DMF), 
N,N-diisopropylethylamine (DiPEA) as base and TBTU as coupling agent, to afford the desired final product 7 in 
moderate yield after flash column chromatography purification.
Biological Evaluation and Molecular Modelling studies
Human norovirus RdRp activity inhibition. The newly synthesised compounds, including the carbox-
ylate ester derivatives 34–35 and 7 from the Core Hopping approach, were evaluated for their enzymatic inhibi-
tion of human norovirus Sydney 2012 (HuNoV (GII.4)) RdRp activity in vitro, using a quantitative fluorescent 
assay29. Compounds were tested at six different concentrations (concentration range examined: 0.1–100 µM) and 
compared to the relative activity of mock treated samples containing the vehicle only (0.5% DMSO [vol/vol]). 
PPNDS [Pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulfonate) tetrasodium salt], a previously 
reported potent inhibitor of NoV RdRp activity27, and 1 were used as positive controls. Dose-dependent inhibi-
tory response curves were used to establish IC50 values for the eight test compounds, as reported in Table 1 (see 
also Supplementary Fig. S1). While IC50 values could be attained for six of the eight compounds tested, 7 only 
reached 20% inhibition at the maximum concentration tested, while 4 reached 15% inhibition at the maximum 
concentration tested (Supplementary Fig. S2).
Compounds bearing modifications at different positions of the terminal hydrophobic ring 1 (2–3, 34–35) 
seem to retain the RdRp inhibitory activity with an IC50 in the range of 13–22 µM, slightly higher in comparison 
Figure 3. Reagents and conditions: (i) HCl, EtOH, reflux, o.n., 79–90%; (ii) NEt3, THF, -10 °C to r.t., 3 h, 75–
99%; (iii) 1 M NaOH/EtOH, EtOH, r.t., 30 min., 33–55%; (iv) Pyridine, r.t., o.n., 68–87%; (v) K3PO4, Pd(dppf)
Cl2, H2O/DMF, MW, 130 °C, 75 min., r.t., o.n. OR Na2CO3, Pd(OAc)2, PPh3, H2O/DME, MW, 85 °C,10 min., 34–
51%; (vi) AcOH, 120 °C, o.n., OR EtOH, reflux, o.n., OR MeOH, reflux, 2 h, 48–65%; (vii) LiOH, THF/MeOH/
H2O, r.t., o.n., OR 2 M NaOH, 1,4-Dioxane, o.n., 49–55%; (viii) HCl, NaNO2, SnCl2, 0 °C, 3 h, 99%.
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with 1 (5.6 µM), but in the same order of magnitude. These results further prove the RdRp inhibitory activity 
associated with the general scaffold of 1 and suggest that introduction of hydrophilic groups into terminal hydro-
phobic ring 1 could improve aqueous solubility without disrupting RdRp inhibitory activity. A similar effect is 
obtained when replacing the terminal hydrophobic ring 2 with an oxazole (5) or benzoimidazole (6), with an IC50 
value of 12.8 and 26.7 µM, respectively. On the other hand, the insertion of a pyrimidine ring at this position (4) 
causes loss of activity, with only partial RdRp inhibition seen at 100 µM.
As mentioned above, 7 did not reach 50% inhibition at the test concentrations, showing only 20% RdRp inhi-
bition at 100 µM. This result suggests that compound 1 planarity and rigidity might have an important role for 
its biochemical activity, as the flexibility conferred by the N,2-diphenylacetamide central core almost completely 
abolishes RdRp inhibition. This effect could be linked with a better overall occupation of the RdRp active site by 
the active inhibitors, as indicated by molecular docking results shown below.
To further confirm RdRp inhibition and exclude any potential false positives from the first fluorescence RdRp 
assay, the eight molecules were then assessed using a gel-shift enzyme activity assay at a fixed concentration of 
Figure 4. Reagents and conditions: (i) Pyr, 0 °C, 4 h, 91%; (ii) 5 M NaOH, MeOH, 70 °C, 3 h, 89%; (iii) Na2CO3, 
Pd(PPh3)4, PhMe/EtOH/H2O, 100 °C, 24 h, 75%; (iv) LiOH, MeOH/H2O, r.t., 2 h, 93%; (v) TBTU, DiPEA, DMF, 
r.t., o.n., 63%.
Compound
Structure
Ar
H
N
S
O
O
O
H
N
N O
O
R
IC50 values [μM]A
2 R = 4-COOH, Ar = Ph 17.2 ± 2.4
3 R = 3-COOH, Ar = Ph 22.5 ± 6.5
34 R = 4-COOEt, Ar = Ph 13.5 ± 5.8
35 R = 3-COOEt, Ar = Ph 18.9 ± 3.1
4 R = H, Ar = 2-Pyrimidine n.d.
5 R = H, Ar = 2-Oxazole 12.8 ± 2.6
6 R = H, Ar = 2-Benzimidazole 26.7 ± 2.0
7
N
H
O
S
O
O
H
N
n.d.
1 R = H, Ar = Ph 5.6B
PPNDS N
HO
O
N
N
O
P
O ONa
ONa
S OO
ONa
NO2
SO O
ONa
1.5 ± 0.25
Table 1. IC50 values of hit compounds against HuNoV (GII.4) RdRp activities. AMean values ± standard 
deviations of triplicate datasets are shown from at least three independent experiments. BActivity data as 
previously reported29.
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100 μM, following a procedure previously adopted by our research group29. PPNDS was used as positive con-
trol and exhibited complete inhibition of transcription at 100 µM (no extension of 32 nucleotide RNA template 
(PE44-NoV) to 44 nucleotides in the presence of an active RdRp). Seven of the eight compounds exhibited com-
plete or almost complete inhibition of norovirus RdRp activity at 100 μM, comparable to the effect observed for 1, 
further confirming their activity as pure polymerase inhibitors (Fig. 5a,b). On the contrary, 7 did not demonstrate 
inhibition of primed elongation activity in this assay (second higher band on gel shift almost identical to the 0.5% 
DMSO control, Fig. 5c), confirming that this linker modification abolishes RdRp inhibitory activity.
Molecular docking studies. In our previously published study29, both competitive binding studies with 
PPNDS and molecular docking simulations indicated that 1 likely occupies the central core of site-B and the 
initial part of site-A of the human norovirus RdRp (Fig. 6). Molecular docking evaluations of the new derivatives 
on the binding site of 1 in the structure of human norovirus RdRp were performed using Glide SP33. Compounds 
4–6 are predicted to occupy the main nucleic acid binding site of HuNoV RdRp in a similar orientation com-
pared to 1, with the N-phenyl/heteroaromatic-benzenesulfonamide portion pointing out from site-B towards 
the RdRp portion in which site-B and site-A overlap (area defined by Arg392), and the differently substituted 
phenyl-pyrazolidine portion occupying the area where PPNDS places its naphthylazo part (Fig. 7a–c), within 
Figure 5. A counter-screen gel-shift assay was used to confirm HuNoV (GII.4) RdRp inhibitory activity of 
compounds 2, 3, 34 and 35 (A), 4, 5, 6 (B) and 7 (C). The eight compounds were examined for inhibition of 
primed elongation activity. PE44-NoV RNA templates (32 nucleotides) were extended (44 nucleotides) by the 
RdRp in the absence of any test compounds (0.5% DMSO [vol/vol] negative control) or with test compounds 
at a fixed concentration of 100 μM. PPNDS and compound 1 and were used as positive controls (100 μM) to 
demonstrate complete inhibition, and no RdRp was used as a negative control. Full-length gels are presented in 
Supplementary Fig. S3.
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the core area of site-B. The added carboxylic group appears to confer an extra interaction with Lys166, further 
stabilising the ligand-protein complex (Fig. 8a, compound 2). This interaction appears to be maintained also in 
the case of the ester analogues 34–35 (Fig. 8b, compound 34). An interesting observation can be made examining 
the predicted binding mode of 4. The presence of the pyrimidine ring seems to increase the attraction towards 
Arg182, pushing the compound away from the predicted binding site, potentially explaining its reduced enzy-
matic activity (Fig. 7a). This effect, which is also present at minor extent for 5, could be a consequence of a differ-
ent electron/charge delocalisation on the terminal part of the molecule due to the different heteroaromatic rings. 
Interestingly, 7, due to the presence of the more flexible N,2-diphenylacetamide central core, assumes a series of 
conformations that do not allow an optimal occupation of the binding area, supporting the observed reduced 
inhibitory effect of RdRp activity (Fig. 9).
Cell-based antiviral effect evaluation. The newly prepared compounds 2–7 and 34–35 were evaluated 
for their antiviral effect against the genogroup V mouse norovirus (MNV) using the mouse macrophage cell line 
RAW264.7. This assay evaluates the ability of the compounds to protect infected cells from the virus-induced 
cytopathic effect, thus being suitable to identify inhibition of virus replication at every step of the virus life 
cycle, and representing a robust cellular assay available for the rapid evaluation of potential norovirus inhibi-
tors. Compounds identified using MNV have shown effects against HuNoV in vitro and in vivo, as in the case of 
nucleoside RdRp inhibitor 2′-C-methylcytidine (2CMC)34–36. Unfortunately, despite not presenting the aqueous 
solubility issues we had previously encountered for 129, no significant antiviral effect could be observed in this 
assay for the new compounds up to the maximum concentration tested. The new structural modifications, despite 
retaining inhibition of the RdRp in an isolated enzyme activity assay and showing no cytotoxic effects at the test 
concentrations in the MNV antiviral assay (Supplementary Table S1), are correlated with a lack of antiviral activ-
ity. As these new structures present the same limitation of most non-nucleoside HuNoV polymerase inhibitors 
reported so far22, we were prompted to apply a different computer-aided strategy to further modify the scaffold 
of 1, with the aim to achieve an antiviral effect in cellular systems. prompting us to attempt further modifications 
on their structure.
Computer-aided flexible alignment approach: new structural modifications on the structure of 1. 
Since both attempts at modifying the structure of 1 did not give the desired result of identifying antiviral hits 
against norovirus replication in cell-based systems, an alternative strategy to identify potential linker replace-
ments for 1 was followed. A conformational search, using MOE conformational search tool37, was performed on 
1 to identify its lowest energy conformation. This conformation was then kept rigid and used to run a flexible 
alignment analysis with the Flexible Alignment tool in MOE37, in order to search for potential three-dimensional 
and functional similarities with an in-house small-molecule database of previously reported non-nucleoside 
inhibitors of viral polymerases, including hepatitis C, Zika and Dengue virus RdRps38–40. In particular, the chosen 
database contains small-molecule compounds reported to have inhibitory activity against viral polymerases, and 
also to show antiviral effects in cell-based assays. From this study, TPB [3-chloro-N-[({4-[4-(2-thienylcarbonyl)-1
Figure 6. Proposed binding mode for 1 in the human norovirus RdRp. 1 (carbon atoms in lilac) occupies site-B 
(turquoise surface) and part of site-A (yellow surface). 1 binds in a different orientation compared to PPNDS 
(carbon atoms in grey), with its phenyl- benzenesulfonamide portion pointing out from the site-B interacting 
through its sulphonamide group with Glu407 and Arg413 and through an arene-cation interaction between 
Arg392 and the benzene ring. Arg392 is in the RdRp portion in which site-B and site-A overlap. The phenyl-
pyrazolidine portion of 1 occupies the area where PPNDS places its naphthylazo portion, the core area of site-B, 
making interactions with the surrounding amino acids (Asp507, Glu510). The binding site area is represented as 
molecular surface. Human norovirus RdRp is represented as turquoise ribbon.
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-piperazinyl]phenyl}amino)carbonothioyl]-1-benzothiophene-2-carboxamide] (48), a recently identified inhibi-
tor of Zika virus RdRp39, resulted as the best match for its structural overlapping with 1, as highlighted in Fig. 10.
Evaluation of inhibition of norovirus RdRp activity using an in vitro fluorescent, de novo RdRp activity assay 
at a fixed concentration of 20 μM revealed that 48, which we promptly synthesised in our laboratory, has a mild 
inhibition of human norovirus RdRp activity (20% inhibition at 20 μM), as reported in the biological evaluation 
studies section below. This preliminary encouraging result, together with the reported antiviral activity demon-
strated for 48 in Vero cells against ZIKV replication39, prompted us to explore this scaffold in the search of new 
norovirus RdRp inhibitors, and most importantly new agents to inhibit HuNoV replication. The structure of 48 
was therefore combined with some structural features from 1 and from some of our previously published norovi-
rus RdRp inhibitors29, leading to the design of a series of new compounds with a non-planar central linker. These 
Figure 8. Proposed binding mode for 2 (A) and 34 (B) in the human norovirus RdRp (PDB ID 4LQ3). 
The added carboxylic acid group appears to confer an extra interaction with Lys166, further stabilising the 
compound 2-protein complex. This interaction appears to be maintained also in the case of the ester analogue 
34. Moreover, the carboxylic acid group is placed at an optimal distance to interact with Arg419. The binding site 
area is represented as molecular surface. Compound 1 binding is reported as comparison (carbon atoms in lilac).
Figure 7. Proposed binding mode for 4 (A), 5 (B) and 6 (C) in the human norovirus RdRp (PDB ID 4LQ3). 
All the three compounds are predicted to occupy the main nucleic acid binding site of HuNoV RdRp in a 
similar orientation compared to 1. The presence of the pyrimidine ring seems to increase the attraction towards 
Arg182, pushing the compound away from the predicted binding site. The binding site area is represented as 
molecular surface. Compound 1 binding is reported as comparison (carbon atoms in lilac).
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new molecules could present improved solubility and better cell-based antiviral profiles in comparison with 1 and 
its analogues, as shown in Fig. 11. In addition, in order to verify the activity associated with the scaffold of 48, a 
few small structural modifications on its scaffold were also planned and carried out.
Chemistry
Synthesis of the newly designed “hybrid” molecules. The 12 newly designed analogues, along with 
the Flexible Alignment hit 48, were synthesised according to a four-step synthetic pathway, as shown in Fig. 12.
Briefly, commercial 1-(4-nitrophenyl)piperazine 61 was treated with the appropriately substituted 
aryl-carboxylic acids or aryl sulfonyl chlorides, to give intermediate nitro-compounds 62a–67a. In particu-
lar, amide-compounds 62a–65a were obtained through a TBTU-assisted coupling reaction in the presence of 
Figure 9. Multiple potential binding modes were obtained for compound 7 in the human norovirus RdRp 
(PDB ID 4LQ3). The N,2-diphenylacetamide central core confers flexibility to the molecule, which assumes a 
series of conformations that do not allow for an optimal occupation of the binding area. The binding site area is 
represented as molecular surface. Compound 1 binding is reported as comparison (carbon atoms in lilac).
Figure 10. Chemical structure of TPB (48, carbon atoms and molecular surface in green) and Flexible 
Alignment results showing its significant degree of structural and molecular surface overlapping with 1 (carbon 
atoms and molecular surface in lilac).
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DiPEA, in DMF at r.t., while sulfonamide intermediates 66a–67a were obtained in DCM at 0 °C to r.t., in the 
presence of NEt3. Nitro-intermediates 62a–67a were then converted into the corresponding substituted aromatic 
amines 62b–67b following a catalytic hydrogenation in EtOH, in the presence of wet activated palladium on 
carbon. Isothiocyanates intermediates 68b–72b were obtained by treating the corresponding aryl-carbonyl chlo-
rides 68a–72a with ammonium isothiocyanate, in acetone under reflux conditions. These intermediates were 
not isolated, but treated in situ with the differently substituted aromatic amines 62b–67b, to give the desired 
final products 48–60. In most cases, formation of unwanted amide-byproducts was observed for this reaction, 
thus explaining the moderate yields obtained in the final step for most of these products. By-products 73–76 
were formed in a particularly high amount in the course of the reaction, therefore they were isolated and fully 
characterised.
Biological Evaluation and Molecular Modelling Studies
Evaluation of the inhibitory activity of HuNoV RdRp for analogues 48–60. The newly prepared 
compounds 48–60 were initially evaluated against norovirus Sydney 2012 RdRp activity in vitro using a quanti-
tative fluorescent assay. Compounds were tested at a fixed concentration of 20 µM and compared to the relative 
activity of mock treated samples. PPNDS and 1 were used as positive controls. Results of this assay are reported 
in Fig. 13. Removal of the chlorine atom from position 2 of the benzothiophene ring (49) or its replacement with 
a bigger trifluoromethyl group (50) appears not to affect much the RdRp inhibitory activity, with an observed 
inhibition which is similar to the effect of 48 (15–20% inhibition at 20 µM). A similar effect is obtained for 51 
and 52 (~15% inhibition at 20 µM), in which the benzothiophene ring has been replaced with a phenyl ring and a 
4-methylphenyl ring respectively. These two rings are structural features present in 1 and in one of its derivatives 
we have previously reported25. Replacement of the thiophene by a furan (53) or by an unsubstituted phenyl ring 
(54) increased the degree of HuNoV RdRp inhibition up to 60% at 20 µM, whereas introduction of a thiazole 
ring (56) does not affect enzymatic inhibition activity. From these observations, the thiophene ring appears not 
to influence inhibitory activity. Derivatives in which the central core of 48 has been used to link the two terminal 
hydrophobic rings of 1 or of its derivatives we have previously reported25 (55, 57, 58) appear to retain the RdRp 
inhibitory activity found for 48 (~20% at 20 µM). A similar effect is obtained when a sulfonyl group, as in our hit 
1, is used to link ring 2, regardless if it is a thiazole (59) or an unsubstituted phenyl ring (60), to the rest of the 
molecule. Interestingly, 73, one of the amide side products formed during the last synthetic step for this series 
of compounds, reduced the polymerase activity of ~40% at 20 µM. 53, the most active compound found in this 
series, also exhibits a significant inhibition of HuNoV RdRp activity at 100 µM in the gel-shift assay, confirming 
the polymerase inhibitory function of the new scaffold. Overall, even if showing a reduced biochemical activity 
in comparison with 1, some of the new derivatives can be considered as modest HuNoV RdRp inhibitors at 
20 µM. This reduced activity in comparison with 1 could to some extent have been expected, since, as seen for 7, 
the reduction in central core planarity/rigidity in the new derivatives would likely reduce their interactions and 
Figure 11. New modifications designed from the structural combination of 1 and 48.
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Figure 12. Reagents and conditions: (i) TBTU, DiPEA, DMF, r.t., 5 h, OR NEt3, DCM, 0 °C to r.t., o.n., 81–99%; 
(ii) H2, 10% Pd/C, EtOH, r.t., 24 h, 78–99%; (iii) CNSH*NH3, Me2CO, reflux, 1 h, quant.; (iv) Me2CO, reflux, 
2 h, 41–78%.
Figure 13. Screening of new derivatives for inhibition of HuNoV (GII.4) RdRp activity. (A) The inhibitory 
effects of 8 compounds were examined against norovirus RdRp activity using a fluorescent activity assay at 
20 μM. Compounds 53 and 54 exhibited almost 60% inhibition. PPNDS (green bar) and compound 1 (black 
bar) were used as positive controls. Percentage of inhibition was normalised to control DMSO (red bar). The 
mean values of triplicate datasets with standard error of the mean are shown. (B) A counter-screen-gel- shift 
assay was used to confirm norovirus RdRp inhibitory activity of 53, the most active compound identified 
in panel (A). PE44-NoV RNA templates (32 nucleotides) were extended (44 nucleotides) by the RdRp in 
the absence of any test compounds (0.5% DMSO [vol/vol] negative control) or with test compounds at a 
fixed concentration of 100 μM. PPNDS and compound 1 and were used as positive controls (100 μM) to 
demonstrate complete inhibition, and no RdRp was used as a negative control. Full-length gels are presented in 
Supplementary Fig. S4.
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optimal fitting of the HuNoV RdRp active site. This hypothesis is in line with molecular docking results obtained 
for 51 and 53, as shown in Fig. 14.
Cell-based antiviral effect evaluation. Since the main scope of this work was to find new norovirus inhib-
itors which show antiviral effects against both the HuNoV RdRp and in norovirus-infected cells, priority was given 
to the evaluation of most of the new molecules for their antiviral activity against MNV in infected RAW cells. The 
nucleoside 2′-C-methylcytidine was used as positive control. The test compounds were evaluated at eight different 
concentrations (range 0.6–100 µM) and their ability to reduce the virus-induced cytopathic effect was assessed.
Five out of 10 compounds tested were found to have an interesting antiviral EC50 in the 20–100 µM range in 
this assay, as reported in Table 2. These new derivatives showed a slightly better EC50 if compared with what we 
had previously found for 129, but more interestingly they were not cytotoxic at the test concentrations, whereas 1 
exhibited a mean half maximal cytotoxic concentration (CC50) of 62.8 μM in a similar MNV cell-based assay29.
As a further step, the five hit compounds which showed activity in the MNV assay were tested against HuNoV 
using a replicon system, i.e. a human gastric tumor-1 (HGT-1) cell line which stably expresses the genome of a 
HuNoV GI.1 virus41. Given that in this system the gene encoding for the major capsid protein is replaced by a 
neomycin resistance gene, no new virus particles will be produced but the non-structural proteins are expressed 
and the replication of the genomic RNA can be studied42.
While 48 and 56 do not display any significant antiviral activity in this second assay, 52, 59 and 60 inhibit the 
viral replication of HuNoV GI with EC50 values in the low micromolar range, as shown in Table 3. The lack of 
activity encountered for 48 and 56 in this assay could be a consequence of several factors, such as differences on 
the envelope and capsid proteins between MNV and HuNoV, which could affect the ability of the two compounds 
to reach the viral RdRp, or different readouts and sensitivity of the two assays in detecting the inhibitory activity 
of the compounds.
Even if showing an interesting EC50 of 8 µM, 60 was found to form crystals starting from a 25 µM concentration, 
thus indicating that its solubility should still be improved. 52 and 59 display instead the most interesting antiviral 
activity profile found so far, with EC50 values against HuNoV GI replication of 6 µM and 10 µM, respectively, pro-
viding a new antiviral scaffold for norovirus which shows promise for additional investigations. Overall, due to 
their low-micromolar inhibitory activity against norovirus replication in vitro, 52 and 59 represent one of the few 
successful examples of non-nucleoside HuNoV polymerase inhibitors which also show antiviral activity against the 
viral replication in a cell-based system. These compounds represent a promising starting point for further struc-
tural optimisation and SAR evaluations. In particular, current research efforts are now ongoing to further improve 
the drug-like properties of these compounds, and to increase their potency in both biochemical and cellular assays.
Conclusions and Future Work
Starting from a rational approach to modify the structure of one HuNoV RdRp inhibitor, 1, which was recently 
identified in our research group, we have explored different modifications on its scaffold, in order to increase 
its drug-like potential as an antiviral agent. Despite the fact that most of the newly modified compounds retain 
inhibitory activity on the viral polymerase, none of them resulted as an antiviral hit when tested in a MNV CPE 
reduction assay. In an attempt to further modify the scaffold of 1 and achieve an antiviral effect in cellular sys-
tems, we have performed a computer-aided approach in order to identify potential similarities between 1 and 
previously reported non-nucleoside inhibitors of viral polymerases, which also display good antiviral activities 
against the replication of different viruses in cell-based assays. Following this rationale, we have recognised sig-
nificant structural similarities between our biochemical hit 1 and a recently reported inhibitor of Zika virus 
polymerase, 48. Rationally combining together different structural features of 1 and 48, we have designed and 
synthesised a new family of 12 modified analogues. Among them, different displayed at least partial inhibition of 
HuNoV RdRp activity in a quantitative fluorescent assay. Most interestingly, five of these compounds were found 
to reduce MNV-induced cytopathic effect with EC50 values in the micromolar range, without being associated 
Figure 14. Proposed binding mode for 51 (A) and 53 (B) to the human norovirus RdRp (PDB ID 4LQ3). 
Although the sulfur atom of the thiourea forms different H-bonds with the surrounding amino acids, the 
reduction in central core planarity/rigidity of the new derivatives does not allow an optimal occupation of the 
HuNoV RdRp active site, potentially reducing the inhibitory activity. The binding site area is represented as 
molecular surface. Compound 1 binding is reported as comparison (carbon atoms in lilac). Human norovirus 
RdRp is represented as turquoise ribbon.
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with significant cytotoxicity. These five hits were then evaluated in a human norovirus replicon assay harbouring 
a genogroup GI, and two of them, 52 and 59, were found to inhibit HuNoV replication with EC50 values in the 
low micromolar range, revealing a new antiviral scaffold for human norovirus. These compounds represent one 
of the few examples of non-nucleoside polymerase inhibitors also showing significant antiviral effect against 
human norovirus replication in a cell-based system. Based on these findings, additional investigations on these 
new structures are currently ongoing to further explore their potential as antiviral agents. In particular, further 
structural optimisation is the main focus of present research efforts, which aim to identify suitable preclinical 
antiviral candidates for the treatment of norovirus infections.
Experimental
Chemistry. All solvents and reagents were used as obtained from commercial sources unless otherwise indi-
cated. All solvents used for chromatography were HPLC grade from Fisher Scientific (UK). All reactions were 
performed under a nitrogen atmosphere29. 1H and 13C-NMR spectra were recorded with a Bruker Avance III HD 
spectrometer operating at 500 MHz for 1H and 125 MHz for 13C, with Me4Si as internal standard. Deuterated 
chloroform was used as the solvent for NMR experiments, unless otherwise stated. 1H chemical shifts values 
(δ) are referenced to the residual non-deuterated components of the NMR solvents (δ  = 7.26 ppm for CHCl3, 
etc.)29. The 13C chemical shifts (δ) are referenced to CDCl3 (central peak, δ = 77.0 ppm). TLC was performed 
on silica gel 60 F254 plastic sheets. Flash column chromatography was performed using silica an Isolera Biotage 
system. UPLC-MS analysis was conducted on a Waters UPLC system with both Diode Array detection and 
Electrospray (+′ve and −′ve ion) MS detection. The stationary phase was a Waters Acquity UPLC BEH C18 
1.7 um 2.1 × 50 mm column. The mobile phase was LC-MS grade H2O containing 0.1% formic acid (A) and 
LC-MS grade MeCN containing 0.1% formic acid (B). Column temperature: 40 °C. Sample diluent: MeCN. 
Sample concentration 1 µg/mL. Injection volume 2 µL29. Three alternative methods were used:
Linear gradient standard method (A): 90% A (0.1 min), 90–0% A (2.5 min), 0% A (0.3 min), 90% A (0.1 min); 
flow rate 0.5 mL/min.
Compound
Structure
N
H
N
N
X
Ar2
N
H
S
Ar1
O
EC50 values [μM]A CC50 values [μM]A
48 (TPB) Ar1 = 2-(3-Cl)-Benzo[b]thiophene, X = CO, Ar2 = 2-Thiophene 58.2 ± 20.7 >100
49 Ar1 = 2-Benzo[b]thiophene, X = CO, Ar2 = 2-Thiophene >100 >100
50 Ar1 = 2-(3-CF3)-Benzo[b]thiophene, X = CO, Ar2 = 2-Thiophene n.d.B n.d.B
51 Ar1 = Ph, X = CO, Ar2 = 2-Thiophene n.d.B n.d.B
52 Ar1 = 4-Me-Ph, X = CO, Ar2 = 2-Thiophene 45.1 ± 10.8 >100
53 Ar1 = 2-(3-Cl)-Benzo[b]thiophene, X = CO, Ar2 = 2-Furan >100 9.4 ± 2.3
54 Ar1 = 2-(3-Cl)-Benzo[b]thiophene, X = CO, Ar2 = Ph >100 4.5 ± 0.7
55 Ar1 = Ph, X = CO, Ar2 = Ph >100 61.9
56 Ar1 = 2-(3-Cl)-Benzo[b]thiophene, X = CO, Ar2 = 2-Thiazole 66.1 ± 12.3 >100
57 Ar1 = 4-Me-Ph, X = CO, Ar2 = Ph >100 >100
58 Ar1 = Ph, X = CO, Ar2 = 2-Thiazole n.d. n.d.
59 Ar1 = Ph, X = SO2, Ar2 = 2-Thiophene 43.8 ± 16.9 >100
60 Ar1 = Ph, X = SO2, Ar2 = Ph 66.6 ± 12.3 >100
2CMC 2.0 ± 1.0 16 ± 2
Table 2. EC50 and CC50 values of 48–60 in the MNV CPE reduction assay. AThe mean values ± standard 
deviations are shown from at least three independent experiments. BNot determined.
Compound
Structure
N
H
N
N
X
Ar2
N
H
S
Ar1
O
M [μM]A
48 (TPB) Ar1 = 2-(3-Cl)-Benzo[b]thiophene, X = CO, Ar2 = 2-Thiophene >100
52 Ar1 = 4-Me-Ph, X = CO, Ar2 = 2-Thiophene 6.1 ± 3.9
56 Ar1 = 2-(3-Cl)-Benzo[b]thiophene, X = CO, Ar2 = 2-Thiazole >100
59 Ar1 = Ph, X = SO2, Ar2 = 2-Thiophene 10.9 ± 11.1
60 Ar1 = Ph, X = SO2, Ar2 = Ph 8.5 ± 2.1
Rupintrivir42 1.5 ± 0.4
Table 3. EC50 values found for the six tested compounds the HuNoV GI replicon assay. AThe mean 
values ± standard deviations of triplicate datasets are shown from at least three independent experiments.
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Linear gradient standard method (B): 90% A (0.1 min), 90–0% A (2.1 min), 0% A (0.8 min), 90% A (0.1 min); 
flow rate 0.5 mL/min.
Linear gradient standard method (C): 90% A (0.1 min), 90–0% A (1.5 min), 0% A (1.4 min), 90% A (0.1 min); 
flow rate 0.5 mL/min.
All compounds tested in biological assays were>95% pure. Purity of intermediates was>90%, unless other-
wise stated. All intermediates were generally prepared according to literature procedures, which are described in 
detail along with compound characterisation in the Supporting Information. Details for the preparation and full 
characterisation of the new target final compounds are given below.
General method for the preparation of N-aryl-4-(5-((3,5-dioxo-1-phenylpyrazolidin-
4-ylidene)methyl)furan-2-yl)benzenesulfonamides 5, 34–35. The appropriately substituted 
1-phenylpyrazolidine-3,5-dione 17–19 (1 mmol) and the differently substituted N-(aryl)-(5-formylfuran-2-yl)
benzenesulfonamides 30, 32 (1 mmol) were suspended in AcOH (15 ml/mmol) and the mixture was stirred at 
120 °C for 3 hours. The mixture was then cooled to room temperature, quenched with water and the precipitate 
obtained was filtered, washed with water and dried under vacuum. The crude product was purified by trituration 
to afford the title compound.
(E)-4-(5-((3,5-dioxo-1-phenylpyrazolidin-4-ylidene)methyl)furan-2-yl)-N-(oxazol-2-yl)ben-
zenesulfonamide (5). Purified by trituration from DCM. Obtained in 65% yield as a light brown solid. 
1H-NMR (DMSO-d6), δ: 12.25 (bs, 1 H), 11.19 (bs, 1 H), 8.54–8.50 (m, 1 H), 8.14–8.11 (m, 2 H), 7.99–7.96 (m, 
2 H), 7.77–7.70 (m, 3 H), 7.64–7.63 (m, 1 H), 7.59–7.58 (m, 1 H), 7.47–7.43 (m, 2 H), 7.32–7.30 (m, 1 H), 7.24–7.18 
(m, 1 H). 13C-NMR (DMSO-d6), δ: 158.5, 158.4, 156.7, 150.7, 150.6, 144.1, 131.7, 129.4, 129.3, 129.2, 127.4, 127.3, 
125.8, 118.7, 116.3, 115.1, 113.7, 113.4, 113.3. UPLC-MS (Method C): Rt 1.84 min, MS [ESI, m/z]: 477.1 [M + H].
Anal. Calcd for C23H16N4O6S: C, 57.98; H, 3.38; N, 11.76. Found: C, 57.69; H, 3.12; N, 11.95.
Ethyl(E)-4-(3,5-dioxo-4-((5-(4-(N-phenylsulfamoyl)phenyl)furan-2-yl)methylene)
pyrazolidin-1-yl)benzoate (34). Purified by trituration from DCM. Obtained in 48% yield as a light 
brown solid. 1H-NMR (DMSO-d6), δ: 11.53 (bs, 1 H), 10.36 (bs, 1 H), 8.56–8.50 (m, 1 H), 8.11 (d, J = 8.4 Hz, 2 H), 
8.03 (d, J = 8.6 Hz, 2 H), 7.96–7.90 (m, 2 H), 7.87–7.84 (m, 2 H), 7.70–7.65 (m, 1 H), 7.58–7.56 (m, 1 H), 7.26–7.23 
(m, 2 H), 7.11 (d, J = 8.6 Hz, 2 H), 7.06–7.03 (m, 1 H), 4.31 (q, J = 7.1 Hz, 2 H), 1.33 (t, J = 7.1 Hz, 3 H). 13C-NMR 
(DMSO-d6), δ: 175.9, 165.7, 165.6, 158.1, 158.0, 150.8, 140.3, 138.8, 132.5, 130.7, 130.6, 129.7, 128.1, 128.0, 126.1, 
124.9, 120.9, 120.8, 115.1, 114.9, 113.9, 61.1, 14.7. UPLC-MS (Method C): Rt 2.30 min, MS [ESI, m/z]: 558.1 
[M + H]. Anal. Calcd for C29H23N3O7S: C, 62.47; H, 4.16; N, 7.54. Found: C, 62.61; H, 3.97; N, 7.39.
Ethyl(E)-3-(3,5-dioxo-4-((5-(4-(N-phenylsulfamoyl)phenyl)furan-2-yl)methylene)
pyrazolidin-1-yl)benzoate (35). Purified by trituration from DCM. Obtained in 58% yield as a light 
brown solid. 1H-NMR (DMSO-d6), δ: 11.28 (bs, 1 H), 10.35 (bs, 1 H), 8.51–8.39 (m, 2 H), 8.10 (d, J = 8.5 Hz, 2 H), 
8.01–7.97 (m, 1 H), 7.85 (d, J = 8.5 Hz, 2 H), 7.78–7.76 (m, 1 H), 7.71–7.68 (m, 1 H), 7.61–7.55 (m, 2 H), 7.26–7.23 
(m, 2 H), 7.12–7.10 (m, 2 H), 7.06–7.03 (m, 1 H), 4.35 (q, J = 7.1 Hz, 2 H), 1.34 (t, J = 7.1 Hz, 3 H). 13C-NMR 
(DMSO-d6), δ: 176.6, 165.9, 165.8, 150.8, 140.3, 140.2, 137.8, 132.5, 131.1, 131.0, 129.9, 129.8, 129.7, 128.2, 128.1, 
126.1, 124.8, 120.9, 120.8, 115.1, 113.9, 113.8, 61.5, 14.6. UPLC-MS (Method C): Rt 2.32 min, MS [ESI, m/z]: 558.1 
[M + H].
Anal. Calcd for C29H23N3O7S: C, 62.47; H, 4.16; N, 7.54. Found: C, 62.32; H, 4.24; N, 7.39.
Preparation of (E)-4-(5-((3,5-dioxo-1-phenylpyrazolidin-4-ylidene)methyl)furan-2-yl)-N-
(pyrimidin-2-yl)benzenesulfonamide (4). To a suspension of 1-phenylpyrazolidine-3,5-dione 19 (0.02 g, 
0.13 mmol) in EtOH (10 ml/mmol) were added 4-(5-formylfuran-2-yl)-N-(pyrimidin-2-yl)benzenesulfonamide 
31 (0.05, 0.15 mmol) and one drop of pyridine. The reaction was stirred under reflux overnight, then cooled to 
room temperature and the precipitate formed was filtered off and washed with cold EtOH and dried under vac-
uum. The crude product was purified by automated flash column chromatography (Biotage Isolera One, SNAP 
KP Sil 10 g) eluting with DCN:MeOH:Net3 100:0:0 v/v increasing to 80:15:5 v/v in 15 CV. Obtained in 51% yield 
as a light brown solid. 1H-NMR (DMSO-d6), δ: 11.90 (bs, 2 H), 8.54–8.47 (m, 3 H), 8.16–8.13 (m, 2 H), 8.10–8.08 
(m, 2 H), 7.79–7.76 (m, 3 H), 7.59–7.58 (m, 1 H), 7.48–7.44 (m, 2 H), 7.23–7.19 (m, 1 H), 7.08–7.04 (m, 1 H). 
13C-NMR (DMSO-d6), δ: 158.1, 157.3, 157.2, 150.8, 150.7, 132.5, 129.4, 129.3, 128.9, 128.3, 125.7, 125.2, 119.1, 
118.8, 117.2, 115.5, 115.3, 113.8, 113.7, 113.0. UPLC-MS (Method C): Rt 1.94 min, MS [ESI, m/z]: 488.1 [M + H].
Anal. Calcd for C24H17N5O5S: C, 59.13; H, 3.52; N, 14.37. Found: C, 59.28; H, 3.40; N, 14.51.
Preparation of (E)-N-(1H-benzo[d]imidazol-2-yl)-4-(5-((3,5-dioxo-1-phenylpyrazolidin-4-ylidene) 
methyl)furan-2-yl)benzenesulfonamide (6). To a solution of 1-phenylpyrazolidine-3,5-dione 19 (0.19 mmol) 
in MeOH (10 ml/mmol) was added N-(1H-benzo[d]imidazol-2-yl)-4-(5-formylfuran-2-yl)benzenesulfonamide 33 
(0.19 mmol). The reaction was stirred at reflux for 2 hours. The precipitate formed was filtered off, washed with cold 
MeOH and dried under vacuum. The crude product was purified by automated flash column chromatography (Biotage 
Isolera One, SNAP KP Sil 10 g) eluting with DCN:MeOH 100:0:0 v/v increasing to 90:10 v/v in 10 CV. Obtained in 55% 
yield as a light brown solid. 1H-NMR (DMSO-d6), δ: 11.38 (bs, 1 H), 8.43–8.35 (m, 1 H), 8.19–8.15 (m, 4 H), 7.79–7.73 
(m, 2 H), 7.72–7.70 (m, 1 H), 7.68–7.63 (m, 1 H), 7.62–7.60 (m, 1 H), 7.46–7.43 (m, 2 H), 7.21–7.18 (m, 3 H), 7.17–7.14 
(m, 2 H), 7.06–7.03 (m, 1 H). 13C-NMR (DMSO-d6), δ: 157.1, 152.5, 151.2, 151.1, 143.3, 136.8, 136.7, 134.6, 130.4, 
129.4, 129.3, 128.3, 128.2, 126.5, 126.4, 125.3, 121.1, 116.5, 116.1, 114.7, 114.6, 114.1, 112.7. UPLC-MS (Method C): Rt 
1.93 min, MS [ESI, m/z]: 526.2 [M + H]. Anal. Calcd for C27H19N5O5S: C, 61.71; H, 3.64; N, 13.33. Found: C, 61.54; H, 
3.52; N, 13.55.
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Preparation of (E)-4-(3,5-dioxo-4-((5-(4-(N-phenylsulfamoyl)phenyl)furan-2-yl)methylene) 
pyrazolidin-1-yl)benzoic acid (2). To a solution of ethyl (E)-4-(3,5-dioxo-4-((5-(4-(N-phenylsulfamoyl)
phenyl)furan-2-yl)methylene)pyrazolidin-1-yl) benzoate 34 (0.18 mmol) in 18 ml of THF:MeOH:H2O (4:1:1) was 
added LiOH (0.53 mmol). The reaction was stirred at room temperature overnight. The mixture was acidified with 
1 N HCl aqueous solution. The solvent was reduced in volume to remove MeOH and THF, and the aqueous layer 
was extracted with EtOAc (3 × 20 ml). The organic layer was dried over MgSO4 and concentrated under vacuum. 
The crude product was purified by trituration from DCM. Obtained in 58% yield as a light brown solid. 1H-NMR 
(DMSO-d6), δ: 13.05 (bs, 1 H), 11.88 (bs, 1 H), 10.27 (s, 1 H), 8.07 (d, J = 8.7 Hz, 2 H), 7.90–7.88 (m, 4 H), 7.81 (d, 
J = 8.7 Hz, 2 H), 7.30 (d, J = 3.6 Hz, 1 H), 7.26–7.22 (m, 2 H), 7.16 (d, J = 3.6 Hz, 1 H), 7.12–7.09 (m, 2 H), 7.05–7.02 
(m, 1 H). 13C-NMR (DMSO-d6), δ: 167.1, 155.6, 151.8, 150.9, 146.2, 144.9, 138.3, 138.0, 134.0, 130.1, 129.8, 129.6, 
128.0, 125.3, 124.7, 124.2, 120.9, 120.8, 117.1, 110.9, 103.6. UPLC-MS (Method C): Rt 2.04 min, MS [ESI, m/z]: 
528.1 [M-H]. Anal. Calcd for C27H19N3O7S: C, 61.24; H, 3.62; N, 7.94. Found: C, 61.50; H, 3.51; N, 8.03.
Preparation of (E)-3-(3,5-dioxo-4-((5-(4-(N-phenylsulfamoyl)phenyl)furan-2-yl)methylene) 
pyrazolidin-1-yl)benzoic acid (3). Ethyl (E)-3-(3,5-dioxo-4-((5-(4-(N-phenylsulfamoyl)phenyl)furan-
2-yl)methylene)pyrazolidin-1-yl)benzoate 35 (0.07 mmol) was added to a mixture of 2 M NaOH aqueous solu-
tion (1 ml) and dioxane (1 ml). The reaction was stirred vigorously at room temperature overnight. The solvent 
was reduced in volume under vacuum and acidified by addition of 1 M HCl solution. The water layer was then 
extracted with EtOAc (3 × 20 ml). The organic portions were combined, dried over MgSO4 and concentrated 
under vacuum. The crude product was purified by automated flash column chromatography (Biotage Isolera One, 
SNAP KP Sil 10 g) eluting with DCM:MeOH 100:0:0 v/v increasing to 80:20 v/v in 15 CV. Obtained in 49% yield 
as a light brown solid. 1H-NMR (DMSO-d6), δ: 13.04 (bs, 2 H), 10.35 (bs, 1 H), 8.54–8.50 (m, 1 H), 8.43–8.39 (m, 
1 H), 8.12–8.09 (m, 2 H), 8.05–7.99 (m, 1 H), 7.86–7.84 (m, 2 H), 7.75–7.73 (m, 1 H), 7.67–7.63 (m, 1 H), 7.58–7.55 
(m, 2 H), 7.26–7.22 (m, 2 H), 7.12–7.10 (m, 2 H), 7.06–7.03 (m, 1 H). 13C-NMR (DMSO-d6), δ: 167.4, 156.2, 151.6, 
150.8, 146.3, 145.5, 140.2, 137.8, 132.6, 129.6, 129.5, 128.0, 125.9, 124.8, 124.3, 120.9, 120.3, 117.4, 109.9, 103.4. 
UPLC-MS (Method C): Rt 2.04 min, MS [ESI, m/z]: 528.1 [M-H]. Anal. calcd for C27H19N3O7S: C, 61.24; H, 3.62; 
N, 7.94. Found: C, 61.01; H, 3.43; N, 8.06.
Preparation of 2-([1,1′-biphenyl]-3-yl)-N-(4-(N-phenylsulfamoyl)phenyl)acetamide (7). 
DiPEA (1.1 mmol) was added to a solution of 2-([1,1′-biphenyl]-3-yl)acetic acid 47 (0.44 mmol), 
4-amino-N-phenylbenzenesulfonamide 43 (0.48 mmol) and TBTU (0.48 mmol) in 3 mL of anhydrous DMF 
under N2 atmosphere at room temperature. The reaction was stirred at r.t. over night, then diluted with EtOAc 
(20 mL) and washed with saturated aqueous NH4Cl solution (15 mL), saturated aqueous NaHCO3 solution 
(15 mL) and brine (10 mL). The organic phase was dried over MgSO4 and concentrated under vacuum.
The crude product was purified by automated flash column chromatography (Biotage Isolera One, SNAP KP 
Sil 10 g) eluting with n-hexane:EtOAc 100:0 v/v increasing to 0:100 v/v in 12 CV. Obtained in 63% yield as an 
off-white solid. 1H-NMR (DMSO-d6), δ: 3.75 (s, 2 H), 6.98–7.02 (m, 1 H), 7.06 (d, J = 8.2 Hz, 2 H), 7.19–7.22 (m, 
2 H), 7.30–7.32 (m, 1 H), 7.35–7.43 (m, 2 H), 7.46–7.49 (m, 2 H), 7.54 (d, J = 7.1 Hz, 1 H), 7.62–7.65 (m, 3 H), 7.68 
(d, J = 8.8 Hz, 2 H), 7.73 (d, J = 8.8 Hz, 2 H), 10.14 (bs, 1 H), 10.55 (bs, 1 H). 13C-NMR (DMSO-d6), δ: 170.2, 143.4, 
140.7, 140.5, 138.5, 136.6, 133.9, 129.5, 129.4, 128.6, 128.3, 128.1, 127.9, 127.1, 125.5, 124.3, 120.5, 119.8, 119.2, 
43.7. UPLC-MS (Method C): Rt 1.96 min, MS [ESI, m/z]: 443.2 [M + H]. Anal. calcd for C26H22N2O3S: C, 70.57; 
H, 5.01; N, 6.33. Found: C, 70.40; H, 5.27; N, 6.17.
General method for the preparation of N-((4-(4-arylpiperazin-1-yl)phenyl)carbamothioyl) aryla-
mides 48–58 and N-((4-(4-(arylsulfonyl)piperazin-1-yl)phenyl)carbamothioyl)arylamides 59–60. 
The appropriate aryl chloride 68a-72a (1 mmol) and ammonium thiocyanate (1 mmol) were dissolved in acetone 
(4 mL/mmol) at 0 °C. Stirring was continued for 1 h at r.t., then the formed precipitate (NH4Cl) was filtered off. 
To the freshly filtered solution, the appropriate aromatic amine 62b–67b (1 mmol) was added. The mixture was 
then stirred under reflux for 1 h. Upon completion of reaction, the resulting precipitate was collected by filtration. 
The crude product was purified by trituration, re-crystallisation or flash column chromatography to afford the 
title compound.
3-Chloro-N-((4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)carbamothioyl)benzo[b]
thiophene-2-carboxamide (48). Purified by trituration from acetone. Obtained in 58% yield as a yellow 
solid. 1H-NMR (DMSO-d6), δ: 11.95 (bs, 1 H), 11.29 (bs, 1 H), 8.19 (dd, J1=7.9 Hz, J2 = 2.0 Hz, 1 H), 7,98 (dd, J1 
= 7.9 Hz, J2 = 2.3 Hz, 1 H) 7.79 (dd, J1 = 5.0 Hz, J2 = 1.2 Hz, 1 H), 7.70–7.63 (m, 2 H), 7.57 (d, J = 9.0 Hz, 2 H), 
7.48 (dd, J1 = 3.7 Hz, J2 = 1.1 Hz, 1 H), 7.16 (dd, J1 = 5.5 Hz, J2 = 3.6 Hz, 1 H), 7.02 (d, J = 9.0 Hz, 2 H), 3.81–3.79 
(m, 4 H), 3.28–3.26 (m, 4 H). 13C-NMR (DMSO-d6), δ: 177.4, 162.8, 161.2, 149.4, 138.0, 137.5, 136.2, 130.2, 130.1, 
129.9, 129.7, 128.8, 127.6, 126.8, 125.6, 124.1, 123.5, 122.5, 115.8, 48.7. UPLC-MS (Method C): Rt 2.18 min, MS 
[ESI, m/z]: 541.0, 543.0 [M + H]. Anal. Calcd for C25H21ClN4O2S3: C, 55.49; H, 3.91; N, 10.35. Found: C, 55.70; 
H, 4.08; N, 10.2239.
N-((4-(4-(Thiophene-2-carbonyl)piperazin-1- yl)phenyl)carbamothioyl)benzo[b]
thiophene-2-carboxamide (49). Re-crystallised from MeOH/H2O. Obtained in 45% yield as a yellow 
solid. 1H-NMR (DMSO-d6), δ: 12.25 (bs, 1 H), 11.76 (bs, 1 H), 8.76 (s, 1 H), 8.10 (dd, J1=8.7 Hz, J2=0.8 Hz, 1 H), 
8.02 (d, J = 7.8 Hz, 1 H), 7.79 (dd, J1 = 5.0 Hz, J2 = 1.1 Hz, 1 H), 7.56–7.48 (m, 3 H), 7.52–7.50 (m, 1 H), 7.49–7.48 
(m, 1 H), 7.16 (dd, J1 = 5.2 Hz, J2 = 3.6 Hz, 1 H), 7.00 (d, J = 9.1 Hz, 2 H), 3.81–3.79 (m, 4 H), 3.27–3.25 (m, 4 H). 
13C-NMR (DMSO-d6), δ: 178.4, 176.6, 163.0, 162.8, 149.4, 141.9, 139.4, 137.5, 137.1, 130.3, 130.1, 129.7, 127.9, 
127.6, 126.7, 125.8, 125.7, 123.4, 115.9, 48.8. UPLC-MS (Method C): Rt 2.02 min, MS [ESI, m/z]: 507.1[M + H]. 
Anal. Calcd for C25H22N4O2S3: C, 59.27; H, 4.38; N, 11.06. Found: C, 59.34; H, 4.23; N, 10.92.
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N-((4-(4-(Thiophene-2-carbonyl)piperazin-1-yl)phenyl)carbamothioyl)-3- (trifluoromethyl)
benzo[b] thiophene-2-carboxamide (50). The crude product was purified by automated flash col-
umn chromatography (Biotage Isolera One, SNAP KP Sil 10 g) eluting with n-hexane:DCM:MeOH 100:0:0 v/v 
increasing to 0:90:10 v/v in 20 CV. Obtained in 41% yield as a yellow solid. 1H-NMR (DMSO-d6), δ: 12.40 (bs, 
1 H), 11.94 (bs, 1 H), 8.27–8.24 (m, 1 H), 7.99–7.96 (m, 1 H), 7.79 (dd, J1 = 6.1 Hz, J2=1.1 Hz, 1 H), 7.73–7.70 
(m, 2 H), 7.66–7.63 (m, 2 H), 7.56 (d, J=9 Hz, 1 H), 7.16 (dd, J1 = 7.1 Hz, J2=3.6 Hz, 1 H), 7.01 (d, J = 9.1 Hz, 
2 H), 3.82–3.80 (m, 4 H), 3.28–3.26 (m, 4 H). 13C-NMR (DMSO-d6), δ: 177.6, 176.6, 172.6, 163.1, 162.8, 162.6, 
149.4, 138.8, 137.5, 133.9, 130.1, 129.8, 129.7, 127.6, 126.9, 125.7, 124.0, 123.3, 115.8, 100.0, 55.4, 48.7. 19F-NMR 
(DMSO-d6), δ ppm: −56.59 (s, 3 F). UPLC-MS (Method C): Rt 2.05 min, MS [ESI, m/z]: 575.1 [M + H]. Anal. 
Calcd for C26H21F3N4O2S3: C, 54.34; H, 3.68; N, 9.75. Found: C, 54.11; H, 3.53; N, 9.98.
N-((4-(4-(Thiophene-2-carbonyl)piperazin-1- yl)phenyl)carbamothioyl)benzamide (51). The 
desired product did not precipitate after cooling the reaction at r.t., as the precipitated solid was in this case 
by-product 73, which was collected by filtration and triturated from acetone. The filtrate was dried under vacuum 
and the crude product was purified by automated flash column chromatography (Biotage Isolera One, SNAP 
KP Sil 10 g) eluting with n-hexane:DCM:MeOH 100:0:0 v/v increasing to 0:95:5 v/v in 20 CV. Obtained in 42% 
yield as a yellow solid. 1H-NMR (CDCl3), δ: 12.47 (bs, 1 H), 9.09 (bs, 1 H), 7.93–7.91(m, 2 H), 7.70–7.67 (m, 1 H), 
7.64–7.62 (m, 2 H), 7.60–7.56 (m, 2 H), 7.50 (dd, J1 = 5.0 Hz, J2 = 1.1, 1 H),7.38 (dd, J1=4.8 Hz, J2 = 1.1, 1 H), 7.10 
(dd, J1 = 5.0 Hz, J2 = 3.6, 1 H), 7.00–6.97 (m, 2 H), 3.95 (t, 4 H), 3.30 (t, 4 H). 13C-NMR (CDCl3), δ: 178.2, 176.6, 
166.9, 163.7, 149.5, 133.7, 131.7, 130.2, 129.2, 129.0, 128.8, 127.5, 126.8, 125.3, 116.3, 49.4. UPLC-MS (Method 
B): Rt 2.18 min, MS [ESI, m/z]: 451.1 [M + H]. Anal. Calcd for C23H22N2O4S2: C, 61.31; H, 4.92; N, 12.43. Found: 
C, 61.20; H, 5.13; N, 12.29.
Isolated by-product N-(4-(4-(thiophene-2-carbonyl)piperazin-1-yl)phenyl)benzamide (73)
Obtained in 37% yield as a yellow solid. 1H-NMR (CDCl3), δ: 10.35 (bs, 1 H), 8.03–8.02 (m, 2 H), 7.88–
7.86 (m, 3 H), 7.66–7.57 (m, 5 H), 7.57 (bs, 1 H), 7.22 (dd, J1=1.2 Hz, J2=3.7 Hz, 1 H), 4.06 (m, 4 H), 3.49 (m, 
4 H).13C-NMR (CDCl3), δ: 176.6, 165.8, 162.9, 137.1, 135.2, 132.1, 130.4, 129.9, 128.8, 128.1, 127.6, 121.8, 37.7. 
UPLC-MS (Method B): Rt 1.92 min, MS [ESI, m/z]: 392.3 [M + H].
4-Methyl-N-((4-(4-(thiophene-2-carbonyl)piperazin-1- yl)phenyl)carbamothioyl)benzamide 
(52). The crude product was purified by trituration from acetone. Obtained in 78% yield as a yellow solid. 
1H-NMR (DMSO-d6), δ: 12.54 (bs, 1 H),11.37 (bs, 1 H), 7.90 (d, J=8.2 Hz, 2 H), 7.79 (dd, J1 = 6.4 Hz, J2 = 1.1 Hz, 
1 H), 7.55 (d, J = 9.1 Hz, 2 H), 7.48 (dd, J1 = 4.2 Hz, J2 = 1.1 Hz, 1 H), 7.34 (d, J = 8.2 Hz, 2 H, H- aromatic), 7.16 
(dd, J1 = 6.4 Hz, J2 = 4.2 Hz, 1 H, H-aromatic), 7.00 (d, J = 9.1 Hz, 2 H, H- aromatic), 3.81–3.80 (m, 4 H), 3.27–3.25 
(m, 4 H), 2.40 (s, 3 H). 13C-NMR (DMSO-d6), δ: 179.1, 176.6, 168.5, 162.8, 149.3, 144.0, 139.7, 137.5, 130.1, 129.7, 
129.5, 129.2, 127.6, 125.6, 115.9, 48.8, 21.6. UPLC-MS (Method B): Rt 1.97 min, MS [ESI, m/z]: 465.2 [M+H]. 
Anal. Calcd for C24H24N4O2S2: C, 62.05; H, 5.21; N, 12.06. Found: C, 62.27; H, 4.97; N, 11.99.
3-Chloro-N-((4-(4-(furan-2-carbonyl)piperazin-1-yl)phenyl)carbamothioyl)benzo[b]
thiophene-2-carboxamide (53). The crude product was purified by trituration from acetone. Obtained 
in 74% yield as a light orange solid. 1H-NMR (CDCl3), δ: 12.11 (bs, 1 H), 10.08 (bs, 1 H), 7.92–7.90 (m, 1 H), 
7.83–7.82 (m, 1 H), 7.55–7.48 (m, 4 H), 7.45–7.44 (m, 1 H), 6.99 (dd, J1=4.4 Hz, J2 = 1.4 Hz, 1 H), 6.91–6.88 (m, 
2 H), 6.44 (dd, J1=5.2 Hz, J2 = 1.4 Hz,), 3.91 (m, 4 H), 3.23–3.21 (m, 4 H). 13C-NMR (CDCl3), δ: 177.4, 176.6, 
160.1, 159.1, 149.5, 147.9, 143.8, 138.9, 136.8, 129.9, 128.8, 126.1, 125.2, 123.9, 122.9, 122.4, 116.8, 116.3, 111.4, 
49.3. UPLC-MS (Method C): Rt 2.14 min, MS [ESI, m/z]: 525.1 [M + H]. Anal. Calcd for C25H21ClN4O3S2: C, 
57.19; H, 4.03; N, 10.67. Found: C, 56.93; H, 3.88; N, 10.91.
N-((4-(4-Benzoylpiperazin-1-yl)phenyl)carbamothioyl)-3-chlorobenzo[b]thiophene-2- 
carboxamide (54). The crude product was purified by trituration from acetone. Obtained in 53% yield as a 
yellow solid. 1H-NMR (CDCl3), δ: 12.20 (bs, 1 H), 10.17 (bs, 1 H), 8.02–8.00 (m, 1 H), 7.93–7.91 (m, 1 H), 7.64–
7.57 (m, 4 H), 7.48–7.46 (m, 5 H), 7.00–6.96 (m, 2 H), 3.97 (m, 2 H), 3.64 (m, 2 H), 3.32–3.20 (m, 4 H). 13C-NMR 
(CDCl3), δ: 177.2, 170.4, 160.2, 149.6, 138.9, 136.8, 135.5, 130.1, 129.9, 129.6, 128.9, 128.6, 127.1, 126.1, 125.2, 
124.0, 122.9, 122.5, 116.5, 49.1. UPLC-MS (Method C): Rt 2.18 min, MS [ESI, m/z]: 535.1 [M + H]. Anal. Calcd 
for C27H23ClN4O2S2: C, 60.61; H, 4.33; N, 10.47. Found: C, 60.38; H, 4.51; N, 10.29.
N-((4-(4-Benzoylpiperazin-1-yl)phenyl)carbamothioyl)benzamide (55). The crude product was 
purified by trituration from acetone. Obtained in 62% yield as a white solid. 1H-NMR (DMSO-d6), δ: 10.28 (bs, 
1 H), 7.97–7.95 (m, 2 H), 7.77 (d, J = 8.6 Hz, 2 H), 7.61 (m, 1 H), 7.55–7.52 (m, 2 H), 7.49–7.47 (m, 6 H), 7.39 (bs, 
2 H), 3.91 (m, 2 H), 3.65 (m, 2 H), 3.36 (m, 4 H). 13C-NMR (DMSO-d6), δ: 178.5, 176.6, 169.5, 165.8, 135.9, 135.3, 
132.0, 130.2, 128.9, 128.8, 128.1, 127.5, 121.8, 36.4. UPLC-MS (Method C): Rt 1.89 min, MS [ESI, m/z]: 445.2 
[M + H]. Anal. Calcd for C25H24N4O2S: C, 67.55; H, 5.44; N, 12.60. Found: C, 67.61; H, 5.17; N, 12.47.
3-Chloro-N-((4-(4-(thiazole-2-carbonyl)piperazin-1-yl)phenyl)carbamothioyl)benzo[b]
thiophene-2-carboxamide (56). The crude product was purified by trituration from acetone. Obtained 
in 43% yield as an off-white solid. 1H-NMR (CDCl3), δ: 12.20 (bs, 1 H) 10.17 (bs, 1 H), 8.01–8.01 (m, 1 H),7.93 (d, 
J = 3.2 Hz, 1 H), 7.93–7.91 (m, 1 H), 7.65–7.57 (m, 5 H), 7.02–6.99 (m, 2 H), 4.64 (m, 2 H), 4.00 (m, 2 H), 3.36 (m, 
4 H). 13C-NMR (CDCl3), δ: 177.2, 176.6, 165.0, 160.1, 154.2, 149.6, 143.2, 138.9, 136.8, 129.9, 129.6, 128.9, 126.1, 
125.2, 124.2, 123.9, 122.9, 116.3, 49.6, 49.1, 46.1, 43.3. UPLC-MS (Method C): Rt 2.20 min, MS [ESI, m/z]: 543.0 
[M + H]. Anal. Calcd for C24H20ClN5O2S3: C, 53.18; H, 3.72; N, 12.92. Found: C, 52.96; H, 3.79; N, 13.03.
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N-((4-(4-Benzoylpiperazin-1-yl)phenyl)carbamothioyl)-4-methylbenzamide (57). The desired 
product did not precipitate after cooling the reaction at r.t., as the precipitated solid was in this case by-product 
74, which was collected by filtration and triturated from acetone. The filtrate was dried under vacuum and the 
crude product was purified by automated flash column chromatography (Biotage Isolera One, SNAP KP Sil 10 g) 
eluting with n-hexane:DCM:MeOH 100:0:0 v/v increasing to 0:95:5 v/v in 25 CV. Obtained in 41% yield as a 
yellow solid. 1H-NMR (CDCl3), δ: 12.50 (bs 1 H), 9.05 (bs 1 H), 7.80 (d, J = 8.3 Hz, 2 H), 7.61 (d, J = 8.9 Hz, 2 H), 
7.35 (d, J = 7.9 Hz, 2 H), 7.48–7.46 (m, 5 H), 6.99–6.95 (m, 2 H), 3.97 (m, 2 H), 3.63 (m, 2 H), 3.31–3.19 (m, 4 H), 
2.38 (s, 3 H). 13C-NMR (CDCl3), δ: 178.3, 170.4, 166.8, 149.5, 144.7, 135.6, 130.4, 129.9, 129.8, 128.9, 128.5, 127.5, 
127.1, 125.2, 116.5, 49.5, 21.6. UPLC-MS (Method C): Rt 2.29 min, MS [ESI, m/z]: 459.2 [M + H]. Anal. Calcd for 
C26H26N4O2S: C, 68.10; H, 5.72; N, 12.22. Found: C, 68.25; H, 5.53; N, 11.97.
Isolated by-product N-(4-(4-benzoylpiperazin-1-yl)phenyl)-4-methylbenzamide (74)
Obtained in 35% yield as a yellow solid. 1H-NMR (CDCl3), δ: 10.20 (bs, 1 H), 7.88 (d, J = 8.2 Hz, 2 H), 7.78 (d, 
J = 8.5 Hz, 2 H), 7.50–7.47 (m, 6 H), 7.37–7.33 (m, 3 H), 3.92 (m, 2 H), 3.63 (m, 2 H), 3.36 (m, 4 H), 2.39 (s, 3 H). 
13C-NMR (CDCl3), δ: 195.6, 176.6, 169.5, 165.6, 142.0, 135.9, 132.4, 130.2, 129.4, 129.3, 128.1, 127.6, 121.8, 38.1, 
21.5. (Method C): Rt 1.75 min, MS [ESI, m/z]: 400.3 [M + H].
N-((4-(4-(Thiazole-2-carbonyl)piperazin-1- yl)phenyl)carbamothioyl)benzamide (58). The 
desired product did not precipitate after cooling the reaction at r.t., as the precipitated solid was in this case 
by-product 75, which was collected by filtration and triturated from acetone. The filtrate was dried under vacuum 
and the crude product was purified by automated flash column chromatography (Biotage Isolera One, SNAP KP 
Sil 10 g) eluting with n-hexane:DCM:MeOH 100:0:0 v/v increasing to 0:90:10 v/v in 20 CV. Obtained in 47% yield 
as a yellow solid. 1H-NMR (DMSO-d6), δ: 12.46 (bs, 1 H), 9.07 (bs, 1 H), 7.94–7.91 (m, 3 H), 7.70–7.67 (m, 1 H), 
7.65–7.62 (m, 2 H), 7.59–7.56 (m, 3 H), 7.02–7.09 (m, 2 H), 4.64 (m, 2 H), 4.01 (m, 2 H), 3.55 (m, 4 H). 13C-NMR 
(DMSO-d6), δ: 178.1, 166.9, 165.1, 159.2, 149.5, 149.6, 143.2, 133.7, 131.8, 129.2, 127.5, 125.3, 124.1, 116.3, 49.7. 
UPLC-MS (Method C): Rt 1.89 min, MS [ESI, m/z]: 452.2 [M + H]. Anal. Calcd for C22H21N5O2S2: C, 58.52; H, 
4.69; N, 15.51. Found: C, 58.48; H, 4.87; N, 15.34.
Isolated by-product N-(4-(4-(thiazole-2-carbonyl)piperazin-1-yl)phenyl)benzamide (75)
Obtained in 29% yield as a yellow solid. 1H-NMR (DMSO-d6), δ: 10.29 (bs, 1 H), 8.07 (m, 2 H), 7.98–7.96 (m, 
2 H), 7.77 (d, J = 8.9 Hz, 2 H), 7.61–7.58 (m, 1 H), 7.55–7.51 (m, 2 H), 7.37–7.34 (m, 2 H), 4.71–4.59 (m, 4 H), 
3.99 (m, 2 H), 3.43 (m, 2 H). 13C-NMR (DMSO-d6), δ: 176.7, 172.4, 165.7, 164.8, 158.9, 144.0, 135.4, 131.9, 128.8, 
128.1, 126.1, 121.9, 31.1. (Method B): Rt 1.89 min, MS [ESI, m/z]: 393.2 [M + H].
N-((4-(4-(Thiophen-2-ylsulfonyl)piperazin-1- yl)phenyl)carbamothioyl)benzamide (59). The 
desired product did not precipitate after cooling the reaction at r.t., therefore the reaction mixture was dried under 
vacuum and the crude product was purified by automated flash column chromatography (Biotage Isolera One, 
SNAP KP Sil 10 g) eluting with n-hexane:DCM:MeOH 100:0:0 v/v increasing to 0:95:15 v/v in 20 CV. Obtained in 
69% yield as a yellow solid. 1H-NMR (DMSO-d6), δ: 12.47 (bs, 1 H), 11.47 (bs, 1 H), 8.09 (dd, J1 = 6.3 Hz, J2 = 1.3, 
1 H), 7.98–7.96 (m, 2 H), 7.00 (dd, J1 = 3.8 Hz, J2 = 1.3, 1 H), 7.68–7.64 (m, 1 H), 7.56–7.51 (m, 4 H), 7.32 (dd, 
J1=6.3 Hz, J2 = 3.8, 1 H), 6.96 (d, J = 9.1 Hz, 2 H), 3.30–3.28 (m, 4 H), 3.09–3.07 (m, 4 H). 13C-NMR (DMSO-d6), δ: 
179.1, 176.6, 168.7, 148.9, 134.8, 134.6, 133.8, 133.5, 132.7, 130.5, 129.1, 128.9, 125.6, 116.3, 48.2, 46.3. UPLC-MS 
(Method C): Rt 2.00 min, MS [ESI, m/z]: 487.1 [M + H]. Anal. Calcd for C22H22N4O3S3: C, 54.30; H, 4.56; N, 11.51. 
Found: C, 54.45; H, 4.36; N, 11.44.
N-((4-(4-(Phenylsulfonyl)piperazin-1-yl)phenyl)carbamothioyl)benzamide (60). The desired 
product did not precipitate after cooling the reaction at r.t., as the precipitated solid was in this case by-product 
76, which was collected by filtration and triturated from acetone. The filtrate was dried under vacuum and the 
crude product was purified by automated flash column chromatography (Biotage Isolera One, SNAP KP Sil 25 g) 
eluting with n-hexane:DCM:MeOH 100:0:0 v/v increasing to 0:95:5 v/v in 20 CV. Obtained in 77% yield as a 
yellow solid. 1H-NMR (DMSO-d6), δ: 12.45 (bs, 1 H), 11.46 (bs, 1 H), 7.98–7.96 (m, 2 H), 7.81–7.75 (m, 3 H), 
7.71–7.64 (m, 3 H), 7.55–7.50 (m, 4 H), 6.94 (d, J=9.1 Hz, 2 H), 3.26–3.24 (m, 4 H), 3.04–3.02 (m, 4 H). 13C-NMR 
(DMSO-d6), δ: 207.4, 199.5, 180.8, 179.0, 176.6, 138.1, 135.1, 133.9, 130.0, 129.1, 128.9, 128.1, 125.6, 116.3, 48.3, 
46.2. UPLC-MS (Method B): Rt 2.37 min, MS [ESI, m/z]: 481.2 [M + H]. Anal. Calcd for C24H24N4O3S2: C, 59.98; 
H, 5.03; N, 11.66. Found: C, 59.76; H, 4.91; N, 11.90.
Isolated by-product N-(4-(4-benzoylpiperazin-1-yl)phenyl)benzamide (76)
Obtained in 14% yield as a yellow solid. 1H-NMR (DMSO-d6), δ: 10.19 (bs, 1 H), 7.95–7.93 (m, 2 H), 7.81–7.76 
(m, 3 H), 7.71–7.64 (m, 4 H), 7.59–7.56 (m, 1 H), 7.53–7.50 (m, 2 H), 7.22–7.00 (m, 2 H), 3.39–3.24 (m, 4 H), 
3.17–3.07 (m, 4 H).13C-NMR (DMSO-d6), δ: 176.6, 165.6, 162.6, 135.4, 135.0, 134.0, 131.9, 130.0, 128.8, 128.1, 
128.0, 121.8, 118.0, 49.8, 46.0. (Method B): Rt 2.15 min, MS [ESI, m/z]: 422.2 [M + H].
Biology
RdRp enzyme inhibition assays. Quantitative RdRp activity and gel-based assays. Fluorescent RdRp 
activity assays were carried out as previously described12,29. Briefly, RdRp activity was quantified by monitor-
ing the formation of double-stranded RNA (dsRNA) from a single stranded homopolymeric template, poly(C) 
(Sigma Aldrich), using the fluorescent dye PicoGreen (Life Technologies, Carlsbad, CA, USA). RdRp assays were 
performed in 384-well plates, and each reaction mixture contained 400 ng enzyme, 45 μM GTP, 10 ng/μL poly(C) 
RNA, 2.5 mM MnCl2, 5 mM dithiothreitol, (DTT), 0.01% bovine serum albumin (BSA), and 0.005% Tween 20 in 
20 mM Tris-HCl, pH 7.5, with a final reaction volume of 25 μL. The PPNDS and compound 1 were used as a pos-
itive controls. RdRps were incubated for 10 mins at 30 °C in the presence of the test compounds or the compound 
vehicle DMSO (0.5% vol/vol) before addition into the reaction mixture, which was then allowed to run 15 min at 
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30 °C then terminated with 10 mM EDTA, followed by PicoGreen staining and dsRNA quantitation. GraphPad 
Prism V6.05 (La Jolla, CA, USA) was used to plot the IC50 values. A secondary gel-based polymerase activity 
assay was used as a counter-screen as described below, to exclude the possibility of RdRp activity enhancement. 
Primed elongation activity was examined in a gel-based assay as previously described12,29 using the RNA template 
(PE44-NoV). Gels were imaged using BioRad (Hercules, CA, U.SA) Geldoc Universal Hood II, running BioRad 
Image Lab software, V4.1, build 16.
MNV and HuNoV cell-based assays. Norovirus. Cells and virus: MNV (virus strain MNV-1.CW1) was 
propagated in RAW 264.7 cells grown in DMEM (Life Technologies, Gent, Belgium) supplemented with 10% or 
2% FBS, 2 mM L-glutamine, 20 mM HEPES, 0.075 g/L sodium bicarbonate, 1 mM sodium pyruvate, 100 U peni-
cillin/mL and 100 lg/mL streptomycin at 37 °C in a humidified atmosphere of 5% CO2. The human norovirus GI.1 
replicon harboring gastric tumor-1 cell line (HGT-NV) (kindly provided by Dr. Ian Goodfellow, University of 
Cambridge) was maintained in DMEM supplemented with 10% FBS, 2mM L-glutamine, 0.075 g/L sodium bicar-
bonate and 1.0 mg/ml of Geneticin (G418; Life Technologies), at 37 °C in a humidified atmosphere of 5% CO234.
Antiviral assay with MNV: The antiviral activity of the Compounds was determined using an MTS [3-(4,5-dim
ethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-based cytopathic effect 
(CPE) reduction assay. RAW 264.7 cells (1 × 104 cells/well) were seeded in a 96-well plate and infected with MNV 
(MOI of 0.001) in the presence (or absence) of a dilution series of Compounds Cells were incubated for 3 days, i.e. 
until complete CPE was observed in infected untreated cells. Then, a MTS-phenazinemethosulfate (MTS/PMS) 
stock solution [(2 mg/mL MTS (Promega, Leiden, The Netherlands) and 46 g/mL PMS (Sigma–Aldrich, Bornem, 
Belgium) in PBS at pH 6–6.5)] was diluted 1/20 in MEM (Life Technologies, Gent, Belgium) and 75 µL were 
added to each well. After 2 h, the optical density (OD) was read at 498 nm. The %CPE reduction was calculated as 
[(ODtreated)MNV − ODVC]/[ODCC − ODVC] × 100, where ODCC represents the OD of the uninfected untreated cells, 
whereas ODVC and (ODtreated)MNV represent the OD of infected untreated cells and virus-infected cells treated with 
a compound concentration, respectively. The 50% effective concentration (EC50) was defined as the compound 
concentration that protected 50% of the cells from virus-induced CPE34.
Cytotoxicity: The cytotoxicity of the Compounds was evaluated by the MTS method, by exposing unin-
fected cells to the same concentrations of compounds for 3 days. The %cell viability was calculated as (ODtreated/
ODCC) × 100, where ODCC is the OD of uninfected untreated cells and ODtreated are uninfected cells treated with 
compound. The CC50 was defined as the compound concentration that reduces the number of viable cells by 50%34.
Antiviral assay with the HGT-NV replicon: The inhibitory effect of Compounds on human norovirus replica-
tion was assessed by quantification of the levels of HuNoV GI replicon RNA and of the reference (housekeeping) 
gene β-actin mRNA [by quantitative reverse transcription polymerase chain reaction (qRT-PCR)]. To this end, 
HGT cells (2000 cells/well) were seeded in 96-well plates, in complete DMEM without the selection marker G418. 
Following an incubation period of 24 h, a serial dilution of rupintrivir was added to the cultures. After 72 h of 
incubation, cell monolayers were washed with phosphate-buffered saline (PBS) and collected for quantification of 
RNA load by qRT-PCR. Intracellular RNA was extracted from cells using the cell-to-cDNA lysis buffer (Ambion, 
Life Technologies). For detection of HuNoV GI replicon RNA, forward (5′-CCG GCT ACC TGC CCA TTC-
3′), reverse (5′-CCA GAT CAT CCT GAT CGA CAA G-3′) primers and probe (5′-FAM-ACA TCG CAT CGA 
GCG AGC ACG TAC-TAMRA-3′) for the neomycin gene were used. For detection of β-actin mRNA, forward 
(5′-GGC ATC CAC GAA ACT ACC TT-3′), reverse (5′-AGC ACT GTG TTG GCG TAC AG-3′) primers and 
probe (5′-HEX-ATC ATG AAG TGT GAC GTG GAC ATC CG-BHQ1–3′) were used. One-step qRT-PCR was 
performed in a 20 µL reaction mixture containing 10 µl 2X iTaq Universal SYBR® Green one step reaction mix 
(Bio-rad, California, USA), 5.17 µl RNAse free water, 0.5 µl of iScript reverse transcriptase (Bio-rad, California, 
USA), 4 µl of the template RNA and either 300 nM of HuNoV GI replicon primers and probe, 300 nM of β-actin 
primers and 200 nM of probe. Cycling conditions were: reverse transcription at 50 °C for 10 min, initial denatur-
ation at 95 °C for 3 min, followed by 40 cycles of denaturation at 95 °C for 15 s, annealing and extension at 60 °C 
for 30 seconds (Roche Lightcycler®96, Roche Diagnostics, Belgium). To determine the relative expression levels 
of HuNoV GI replicon RNA, β-actin was used as a normalizer and ratios were calculated using the Pfaffl method. 
The Expression Ratio (HuNoV GI Replicon/β-actin) was calculated as: Expression Ratio = (E HuNoV)ΔCT, HuNoV (CC – 
TC)/(Eβ-actin)ΔCT, β-actin (CC – TC), where E HuNoV and Eβ-actin represent the amplification efficiency (E  = 10–1/slope) for the 
HuNoV GI replicon and β-actin qRT-PCR reactions, respectively. ΔCT, HuNoV (CC – TC) is the Ct of untreated 
control cells (CC) minus the Ct of cells treated with a compound concentration (TC) obtained with HuNoV GI 
replicon primers and probe. ΔCT, β-actin (CC – TC) is the Ct of untreated control cells (CC) minus the Ct of cells 
treated with a compound concentration (TC) obtained with β-actin primers and probe. Efficiency values (E HuNoV 
and Eβ-actin) were determined for each qRT-PCR reaction. The 50% effective concentration (EC50) was defined as 
the compound concentration that resulted in a 50% reduction of the relative HuNoV replicon RNA levels34.
Molecular modelling. All molecular docking studies were performed on a Viglen Genie Intel®CoreTM 
i7–3770 vPro CPU@ 3.40 GHz × 8 running Ubuntu 16.04. Molecular Operating Environment (MOE) 2018.1033 
and Maestro (Schrödinger Release 2017–1)33 were used as molecular modelling software. The RdRp structure n 
complex with PPNDS was downloaded from the PDB data bank (http://www.rcsb.org/; PDB code 4LQ3). The 
protein was pre-processed using the Schrödinger Protein Preparation Wizard by assigning bond orders, add-
ing hydrogens and performing a restrained energy minimization of the added hydrogens using the OPLS_2005 
force field. Ligand structures were built with MOE and then prepared using the Maestro LigPrep tool by energy 
minimising the structures (OPLS_2005 force filed), generating possible ionization states at pH 7 ± 2, generating 
tautomers and low-energy ring conformers. An 11 Å docking grid (inner-box 10 Å and outer-box 21 Å) was pre-
pared using as centroid the co-crystallised PPNDS. Molecular docking studies were performed using Glide SP 
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precision keeping the default parameters and setting 5 as number of output poses per input ligand to include in 
the solution. The output poses were saved as mol2 file. The docking results were visually inspected for their ability 
to bind the active site.
The Flexible Alignment was performed using MOE2018.10. The MOE flexible alignment tool generates dif-
ferent possible conformations for each molecule present in the input database (in-house small-molecule database 
of reported non-nucleoside inhibitors of viral polymerases, previously prepared in MOE) that could overlap the 
conformation of the assigned template, which is kept rigid (compound 1). The quality of the alignment is eval-
uated by a score which is a sum of the internal strain of the obtained conformation (the smaller, the better) and 
the overlap of molecular features (aromatic regions, donors/acceptors). MOE, for each alignment performed, 
evaluates the average internal energy of the ligands U, the similarity score F (the lower value is, the better the 
two structures overlap) and the value S (sum of U and F values obtained for each alignment). A good alignment 
should present a dU value (the average strain energy of the molecules in the alignment in kcal/mol) lower than 
1 kcal/mol meaning that the obtained conformations are not energetically disadvantaged. The obtained data from 
the Flexible Alignment with dU of 0.0 (no energy penalty) were kept and ranked according to the lowest S value. 
TPB (48) resulted the best match for its structural overlapping.
The conformation of 1 required for the Flexible Alignment was obtained using MOE conformational search 
tool, using the default parameters, selecting Stochastic as search method and setting RMS Gradient to 0.001 and 
the RMSD Limit to 0.15. 159 conformations were generated and among them the best in terms of dE (the strain of 
the conformation relative to the lowest energy conformation with the same stereochemistry configuration. Value 
of 0 indicate the best result) and E (value of the potential energy of the conformation) was chosen as template for 
the Flexible Alignment.
The Glide-Based Core Hopping tool of Maestro32 was used to perform a scaffold replacement. The structure 
of compound 1 docked into the RdRp binding site was used as template ligand keeping as fixed the two terminal 
hydrophobic rings and let the program replacing the original scaffold with new optimal linkers. The new ligands 
are then automatically docked on the receptor and ranked and scored according to the docking results. The default 
parameters were used, using as docking grid the one previously generated for the SP docking studies (see above).
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